19 publications
Name | Date | Type | Actions |
---|---|---|---|
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
Public releases | ||
Rapport financier semestriel 2023 (french) Rapport financier semestriel 2023 (french) |
Half Year Report | ||
2023 half-year Results Sales: €256m (-5.4% as reported) |
Public releases | ||
2023 Half-Year Results Contents |
Half Year Report | ||
Rapport financier semestriel 2022 (french) Rapport financier semestriel 2022 (french) |
Half Year Report | ||
Q1 2023 Sales: €145M Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates. |
Public releases | ||
Availability of the 2022 universal registration document On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
2022 ANNUAL RESULTS Annual sales: €540m (up 3.6% as reported) |
Public releases | ||
Annual sales 2022 Total group Sales: €540 million (up 3.6% as reported) |
Public releases | ||
Vetoquinol acquires Equity Stake in Plant Advanced Technologies PAT Lure and Nancy - November 13, 2017: Vetoquinol, a leading player in the animal health sector, and Plant Advanced Technologies PAT, a plant biotechnology company, announce Vetoquinol’s acquisition of an equity stake in Plant Advanced Technologies PAT. The transaction was carried out via a €500,000 reserved capital increase at a price of €25 per share resulting in the veterinary group holding an equity stake of just over 2% in PAT. |
Public releases |